Compare · MDLN vs SGHT
MDLN vs SGHT
Side-by-side comparison of Medline Inc. (MDLN) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 182.4x SGHT ($242.1M).
- Over the past year, MDLN is down 17.7% and SGHT is up 12.1% - SGHT leads by 29.8 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 8 for SGHT).
- MDLN has more recent analyst coverage (25 ratings vs 19 for SGHT).
- Company
- Medline Inc.
- Sight Sciences Inc.
- Price
- $33.55-0.15%
- $4.55+1.79%
- Market cap
- $44.15B
- $242.1M
- 1M return
- -20.16%
- -13.83%
- 1Y return
- -17.69%
- +12.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2021
- News (4w)
- 20
- 8
- Recent ratings
- 25
- 19
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)
Latest SGHT
- Director Fountain Tamara was granted 28,261 shares, increasing direct ownership by 35% to 109,650 units (SEC Form 4)
- Director Encrantz Staffan was granted 28,261 shares, increasing direct ownership by 2% to 1,420,183 units (SEC Form 4)
- Director Burbach Gerhard F was granted 28,261 shares, increasing direct ownership by 30% to 123,207 units (SEC Form 4)
- Director Zurbay Donald was granted 28,261 shares, increasing direct ownership by 17% to 193,613 units (SEC Form 4)
- Director Mazzacco Catherine was granted 28,261 shares, increasing direct ownership by 69% to 69,276 units (SEC Form 4)
- Sight Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Sight Sciences Inc.
- Chief Operating Officer Bauerlein Alison sold $65,167 worth of shares (12,728 units at $5.12), decreasing direct ownership by 2% to 688,893 units (SEC Form 4)
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits